Profiling impurities in MDMA (also known as ecstasy) is essential to forensic science as different profiles can provide clues about the source. Two researchers from Michigan State University (Michigan, USA) investigated the effect of liquid–liquid extraction (LLE), headspace solid-phase microextraction (HS–SPME), and different gas chromatography temperature programmes highlighting the need for standardized procedures.
Photo Credit: Andrew Bret Wallis/Getty Images
3,4-methylenedioxy-methamphetamine MDMA (also known as ecstasy) is a widely available synthetic psychoactive drug that can contain a wide range of impurities and cutting agents. Profiling impurities in MDMA is essential to forensic science as different profiles can provide clues about the source. There are a number of standardized extraction and chromatographic methods used by labs; however, it can be difficult to make direct comparisons between data from different sources as key parameters can vary. Two researchers from Michigan State University (Michigan, USA) investigated the effect of liquid–liquid extraction (LLE), headspace solid-phase microextraction (HS–SPME), and different gas chromatography temperature programmes highlighting the need for standardized procedures.1
Ruth Smith, coauthor of the paper, told The Column: “Profiling MDMA exhibits is important to law enforcement so that connections between exhibits and/or manufacturers can be made based on the components and impurities present.” Analysts typically extract MDMA samples using LLE or HS–SPME and analyze by performing gas chromatography–mass spectrometry (GC–MS). According to Smith, however, there is more of a push for statistical analyses to reduce subjectivity, thereby increasing the need for a standardized method.
Five exhibits of MDMA were provided by the Michigan Forensic Science Division. Seven tablets from each exhibit were prepared by LLE and HS–SPME and analyzed using GC–MS with two different temperature programmes. Principle component analysis was performed to statistically assess chromatograms.
It was found that HS–SPME extracted more compounds than LLE because of the preconcentration step. For example, pheny‑2‑propanone (P2P), a common precursor, and the intermediate MDP2P, present when isosafrole or piperonal are used as the starting material, were present in HS–SPME extractions but not LLE. Furthermore, a longer temperature programme of 53 min compared to 36 min gave a higher level of discrimination because of a longer hold time. However, this may not be an option for forensic laboratories and an intermediate may have to be found, according to the paper. Smith told The Column: “This work is important as it may be the first step towards a more standardized approach to impurity profiling.” — B.D.
Reference
1. K.M. McManaman and R. Waddell Smith, Journal of Forensic Sciences59(2) 327–336 (2014).
This article is from The Column. The full issue can be found here
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
Inside the Laboratory: The Richardson Group at the University of South Carolina
November 20th 2024In this edition of “Inside the Laboratory,” Susan Richardson of the University of South Carolina discusses her laboratory’s work with using electron ionization and chemical ionization with gas chromatography–mass spectrometry (GC–MS) to detect DBPs in complex environmental matrices, and how her work advances environmental analysis.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
Infographic: Be confidently audit ready, at any time and reduce failures in pharma QC testing
November 20th 2024Discover how you can simplify the audit preparation process with data integrity dashboards that provide transparency to key actions, and seamlessly track long-term trends and patterns, helping to prevent system suitability failures before they occur with waters_connect Data Intelligence software.
Critical Role of Oligonucleotides in Drug Development Highlighted at EAS Session
November 19th 2024A Monday session at the Eastern Analytical Symposium, sponsored by the Chinese American Chromatography Association, explored key challenges and solutions for achieving more sensitive oligonucleotide analysis.